Category: <span>News</span>
New domestic supply chain: Gold-199
MURR is now producing Au-199 in partnership with the Department of Energy Isotope Program.
University of Missouri Board of Curators approves capital projects
The University of Missouri Research Reactor (MURR) will get an approximately 40,000-square-foot addition to expand the existing facility with an estimated completion date in fall 2024.
MU research reactor helps supply critical medical isotopes during global disruption
Due to a recent unexpected reactor shutdown in Europe, the University of Missouri Research Reactor (MURR) has increased its production of critical medical radioisotopes in an effort to help alleviate the anticipated disruption on the global supply chain.
ABK Biomedical Announces Enrollment Initiation of First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
ABK Biomedical, Inc., a MURR partner, has announced the initiation of a First-in-Human study with their Eye90 microspheres™
MU research reactor still breaking new ground in 5th decade of operation
After more than 50 years supporting research and industry as the most powerful university research reactor in the country, the University of Missouri Research Reactor (MURR) is still making waves.
Discovery of complex tunable magnetic order in a topological material tied to exotic electrical conduction
New research is promising for technologies such as high-precision sensors, resistanceless nanowires, magnetic storage media, and quantum computers.
New strongly correlated magnetic phase at intersection of quantum and classical physics in perovskite ruthenate
A new study by a team of researchers including MURR scientist Tom Heitmann and led by Prof. Deepak Singh of the MU Department of Physics & Astronomy suggests the discovery of a new magnetic phase at the cross-road of classical and quantum physics in strongly correlated perovskite materials.
Researchers at MU and MURR develop potential cancer agents
A new study by researchers at MU and MURR advances development of theranostic pairs for potential diagnosis and treatment of cancer.
MU Research Reactor to supply radioisotope for targeted cancer therapy
MURR® has entered into an exclusive agreement to provide no-carrier-added lutetium-177 to Advanced Accelerator Applications, SA (AAA), a Novartis company.
Researchers are exploring theranostic pairs for cancer diagnosis and treatment
Researchers at MU, MURR, and the Truman Memorial Veterans’ Hospital have published a new study evaluating the radioisotopes technetium and rhenium as theranostic agents for diagnosing and treating certain cancers.